173 related articles for article (PubMed ID: 38689338)
1. The role of the soft palate dose regarding normal tissue toxicities in older adults with head and neck cancer undergoing definitive radiotherapy.
Bitz HC; Sachpazidis I; Zou J; Schnell D; Baltas D; Grosu AL; Nicolay NH; Rühle A
Radiat Oncol; 2024 Apr; 19(1):53. PubMed ID: 38689338
[TBL] [Abstract][Full Text] [Related]
2. SPECT/CT-guided elective nodal irradiation for head and neck cancer: Estimation of clinical benefits using NTCP models.
de Veij Mestdagh PD; Janssen T; Lamers E; Carbaat C; Hamming-Vrieze O; Vogel WV; Sonke JJ; Al-Mamgani A
Radiother Oncol; 2019 Jan; 130():18-24. PubMed ID: 30087057
[TBL] [Abstract][Full Text] [Related]
3. Relationship between patient and physician-rated xerostomia and dose distribution to the oral cavity and salivary glands for head and neck cancer patients after radiotherapy.
Kaae JK; Johnsen L; Hansen CR; Kristensen MH; Brink C; Eriksen JG
Acta Oncol; 2019 Oct; 58(10):1366-1372. PubMed ID: 31241381
[No Abstract] [Full Text] [Related]
4. Physical and Radiobiological Evaluation of Accelerated Intensity Modulated Radiotherapy for Locally Advanced Head and Neck Cancer and Comparison with Short-Term Clinical Outcomes.
Buchapudi RR; Manickam R; M R AK; C R TP; Chandraraj V; Pyakuryal A; Narayanasamy G
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2463-2470. PubMed ID: 31450921
[TBL] [Abstract][Full Text] [Related]
5. Patient anatomy-specific trade-offs between sub-clinical disease coverage and normal tissue dose reduction in head-and-neck cancer.
Kaplan LP; Holm AIS; Eriksen JG; Heijmen BJM; Korreman SS; Rossi L
Radiother Oncol; 2023 May; 182():109526. PubMed ID: 36764458
[TBL] [Abstract][Full Text] [Related]
6. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.
Deneuve S; Bastogne T; Duclos M; Mirjolet C; Bois P; Bachmann P; Nokovitch L; Roux PE; Girodet D; Poupart M; Zrounba P; Claude L; Ferella L; Iacovelli NA; Foray N; Rancati T; Pereira S
Tumori; 2023 Apr; 109(2):173-185. PubMed ID: 35578746
[TBL] [Abstract][Full Text] [Related]
7. Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation.
Heukelom J; Kantor ME; Mohamed ASR; Elhalawani H; Kocak-Uzel E; Lin T; Yang J; Aristophanous M; Rasch CR; Fuller CD; Sonke JJ
Radiother Oncol; 2020 Jan; 142():100-106. PubMed ID: 31431381
[TBL] [Abstract][Full Text] [Related]
8. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.
Rühle A; Sprave T; Kalckreuth T; Stoian R; Haehl E; Zamboglou C; Laszig R; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Apr; 15(1):81. PubMed ID: 32299456
[TBL] [Abstract][Full Text] [Related]
9. Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma.
Refaat T; Choi M; Thomas TO; Bacchus I; Agulnik M; Pelzer HJ; Mellott AL; Rademaker AW; Liu D; Sathiaseelan V; Mittal BB
Am J Clin Oncol; 2015 Dec; 38(6):588-94. PubMed ID: 24136140
[TBL] [Abstract][Full Text] [Related]
10. Multivariable normal tissue complication probability model-based treatment plan optimization for grade 2-4 dysphagia and tube feeding dependence in head and neck radiotherapy.
Kierkels RGJ; Wopken K; Visser R; Korevaar EW; van der Schaaf A; Bijl HP; Langendijk JA
Radiother Oncol; 2016 Dec; 121(3):374-380. PubMed ID: 27614681
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy.
Lee TF; Fang FM
Radiother Oncol; 2013 Mar; 106(3):352-8. PubMed ID: 23333019
[TBL] [Abstract][Full Text] [Related]
12. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
[TBL] [Abstract][Full Text] [Related]
13. The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly.
Haehl E; Rühle A; Klink R; Kalckreuth T; Sprave T; Gkika E; Zamboglou C; Meiß F; Grosu AL; Nicolay NH
Radiat Oncol; 2021 Jun; 16(1):105. PubMed ID: 34118984
[TBL] [Abstract][Full Text] [Related]
14. Direct use of multivariable normal tissue complication probability models in treatment plan optimisation for individualised head and neck cancer radiotherapy produces clinically acceptable treatment plans.
Kierkels RG; Korevaar EW; Steenbakkers RJ; Janssen T; van't Veld AA; Langendijk JA; Schilstra C; van der Schaaf A
Radiother Oncol; 2014 Sep; 112(3):430-6. PubMed ID: 25220369
[TBL] [Abstract][Full Text] [Related]
15. Helical tomotherapy for head and neck squamous cell carcinoma: dosimetric comparison with linear accelerator-based step-and-shoot IMRT.
Murthy V; Master Z; Gupta T; Ghosh-Laskar S; Budrukkar A; Phurailatpam R; Agarwal J
J Cancer Res Ther; 2010; 6(2):194-8. PubMed ID: 20622367
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric Evaluation of Incorporating Patient Geometric Variations Into Adaptive Plan Optimization Through Probabilistic Treatment Planning in Head and Neck Cancers.
Liu Q; Liang J; Zhou D; Krauss DJ; Chen PY; Yan D
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):985-997. PubMed ID: 29976511
[TBL] [Abstract][Full Text] [Related]
17. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy.
Brodin NP; Kabarriti R; Pankuch M; Schechter CB; Gondi V; Kalnicki S; Guha C; Garg MK; Tomé WA
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):540-552. PubMed ID: 30496877
[TBL] [Abstract][Full Text] [Related]
18. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
[TBL] [Abstract][Full Text] [Related]
19. Quality of life and toxicity guided treatment plan optimisation for head and neck cancer.
van der Laan HP; van der Schaaf A; Van den Bosch L; Korevaar EW; Steenbakkers RJHM; Both S; Langendijk JA
Radiother Oncol; 2021 Sep; 162():85-90. PubMed ID: 34237344
[TBL] [Abstract][Full Text] [Related]
20. Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial.
Held T; Lang K; Regnery S; Weusthof K; Hommertgen A; Jäkel C; Tonndorf-Martini E; Krisam J; Plinkert P; Zaoui K; Freudlsperger C; Moratin J; Krauss J; Harrabi SB; Herfarth K; Debus J; Adeberg S
Radiat Oncol; 2020 Aug; 15(1):190. PubMed ID: 32758267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
